Bristol Myers' China partner touts Phase 3 success for EGFRxHER3 bispecific ADC

Bristol Myers Squibb’s foray into cancer antibody-drug conjugates and bispecifics appears to be bearing fruit. Chinese startup Biokin, which partnered with Bristol Myers through its subsidiary SystImmune in 2023, said that an EGFRxHER3 bispecific ADC ...